Loading patent…
AssigneeF. Hoffmann-La Roche AG
InventorsPaul DELMAR, Dorothee Foernzler, Stefan Scherer
Estimating the term…
The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”).
A method for improving treatment effect in a patient suffering from gastric cancer by adding bevacizumab to a chemotherapy regimen, said method comprising:
An in vitro method for the identification of a patient responsive to or sensitive to the addition of bevacizumab treatment to a chemotherapy regimen, said method comprising determining the expression level of neuropilin in a sample from a patient suspected to suffer from or being prone to suffer from gastric cancer, whereby a decreased level of neuropilin relative to a control level determined in patients suffering from gastric cancer is indicative of a sensitivity of the patient to the addition of bevacizumab to said regimen.
A kit useful for identifying a patient suffering from, suspected to suffer from, or being prone to suffer from gastric cancer as being responsive to or sensitive to the addition of bevacizumab treatment to a chemotherapy regimen, the kit comprising oligonucleotides or polypeptides capable of determining the expression level of neuropilin and instructions for use of the oligonucleotides or polypeptides to determine the level of neuropilin in a sample from the patient, wherein a decrease in the expression level of neuropilin identifies a patient as being responsive to or sensitive to the addition of bevacizumab treatment to a chemotherapy regimen.
Dependencies are inferred from the claim text.